Study wrapper · #125
Effects of Semaglutide on Cardiometabolic Risk in People with Obesity, With and Without Type 2 Diabetes: A Retrospective Observational Study.
Editor's note
A small retrospective observational cohort (70 adults with obesity, 42 with and 28 without type 2 diabetes) reporting real-world semaglutide effects on cardiometabolic markers and body composition. The associations are broad and directionally consistent with trial evidence: significant reductions in body weight (-9 kg), waist circumference (-8 cm), HbA1c (-1.1%), systolic blood pressure (-7.5 mmHg), and visceral fat area (-30.1 cm2), with skeletal muscle relatively preserved, glycemic gains larger in the diabetic subgroup, and baseline HbA1c and visceral adiposity predicting response. The body-composition detail via bioimpedance is a nice addition. But the constraints are substantial: n=70, single-arm and retrospective with no control group, so no causal or comparative claim is supportable, and bioimpedance is an approximate method for body composition. Predictor findings from a sample this size are exploratory. Read this as corroborating real-world observation, consistent with the much stronger STEP trial base, rather than as independent evidence of effect magnitude.
Plain-language abstract
This study reviewed records of 70 adults with obesity, 42 who also had type 2 diabetes and 28 who did not, all of whom were given semaglutide. Researchers measured changes in weight, waist size, blood sugar, blood pressure, cholesterol, markers of insulin resistance, and body composition (fat and muscle) using a body-scan method called bioelectrical impedance. There was no comparison group; everyone received the drug. On average, patients lost about 9 kg of weight and 8 cm from their waist, their long-term blood sugar (HbA1c) dropped about 1.1 points, systolic blood pressure fell about 7.5 mmHg, and belly (visceral) fat dropped substantially. Muscle mass was largely preserved. Blood-sugar improvements were greater in those with diabetes. Patients who started with higher blood sugar and more belly fat tended to respond more strongly. The authors describe these as real-world improvements in weight and metabolic health. Because this was a small look-back study with no control group, it cannot prove the drug alone caused the changes, and the results should be seen as supporting, not proving, its effects.